AR and prostate carcinoma: As an antiandrogen drug, bicalutamide can bind to the androgen receptor in the body with high intensity, thus reducing the growth-promoting effect of testosterone and dihydrotestosterone on cancer cells, maximally controlling the metastasis of prostate cancer cells and consolidating the therapeutic effect.